To the Editor We read with great interest the article entitled “Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.”1 The authors concluded that tenofovir treatment was associated with a significantly lower risk of hepatocellular carcinoma (HCC) than entecavir treatment in treatment-naive patients with chronic hepatitis B. This study may potentially affect clinical practice, although Flemming and Terrault2 have stated in their accompanying editorial that this study should not lead to a widespread paradigm shift in selecting tenofovir treatment over entecavir treatment.